TrialTargeted oncology2016

Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.

Oscar Arrieta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.